Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892770 | 1.00 | MME (0.47) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL6366655 | 1.00 | MME (0.47) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL18010311 | 0.92 | MME (0.50) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL10960732 | 0.79 | FAAH (0.54) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL1476947 | 0.78 | SMN1; SMN2 (0.47) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL10076082 | 0.78 | ALDH1A1 (0.50) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL964581 | 0.78 | SMN1; SMN2 (0.47) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL4811341 | 0.78 | SMN1; SMN2 (0.47) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL4811735 | 0.78 | SMN1; SMN2 (0.47) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL6309640 | 0.78 | SMN1; SMN2 (0.47) | MMEACECPA1ACE2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119529814-A | Self-generated composite acid fracturing fluid without preparation and application thereof | 中国石油天然气股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-109908361-B | Targeting polypeptide-cucurbituril supramolecular assembly based on regulation and control of microtubule aggregation and preparation method and application thereof | 南开大学 | 2020-07-31 | — | — | CN | claimed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| CN-119355279-B | Method for enriching protein containing reduced sulfhydryl based on chemical covalent bonding technology | 国科大杭州高等研究院 | 2025-03-28 | — | — | CN | disclosed |
| CN-119529814-A | Self-generated composite acid fracturing fluid without preparation and application thereof | 中国石油天然气股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119355279-A | Method for enriching protein containing reduced sulfhydryl based on chemical covalent bonding technology | 国科大杭州高等研究院 | 2025-01-24 | — | — | CN | disclosed |
| EP-4043076-B1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | GENEFRONTIER CORP (JP) | 2024-06-26 | — | — | EP | disclosed |
| US-20240092836-A1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | GENEFRONTIER CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| CN-116888138-A | Radiopharmaceutical conjugate compositions and uses thereof | 瑞择生物公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4043076-A1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | GeneFrontier Corporation (JP) | 2022-08-17 | — | — | EP | disclosed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| WO-2021070696-A1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | ジーンフロンティア株式会社 | 2021-04-15 | — | — | WO | disclosed |
| CN-109908361-B | Targeting polypeptide-cucurbituril supramolecular assembly based on regulation and control of microtubule aggregation and preparation method and application thereof | 南开大学 | 2020-07-31 | — | — | CN | disclosed |
| US-20160083516-A1 | CROSSLINKED POLY-DEPSIPEPTIDE COPOLYMERS AND METHODS OF MAKING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20160083516-A1 | CROSSLINKED POLY-DEPSIPEPTIDE COPOLYMERS AND METHODS OF MAKING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20160083516-A1 | CROSSLINKED POLY-DEPSIPEPTIDE COPOLYMERS AND METHODS OF MAKING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| WO-2007074390-A2 | PROCESS FOR PREPARING RHODANINE-3-ACETIC ACID: A KEY INTERMEDIATED OF EPALRESTAT | KHAMAR BAKULESH MAFATLAL (IN) | 2007-07-05 | — | — | WO | disclosed |
| US-4055663-A | Halogenated acylamino acids as fungicides | NATIONAL PATENT DEVELOPMENT CORPORATION (US) | 1977-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092836-A1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | CXCL10, CXCR3, CXCR6 | MME 1528/4885ACE 3306/4885CPA1 279/4885 |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | MME 1493/4885ACE 3534/4885CPA1 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.